Tecentriq (atezolizumab) / Roche 
Welcome,         Profile    Billing    Logout  
 31 Diseases   517 Trials   517 Trials   19434 News 


12345678910111213...238239»
  • ||||||||||  Tecentriq (atezolizumab) / Roche
    Journal:  Biological Agents for Treating Atezolizumab-Induced Psoriasis in Small-Cell Lung Cancer: A Case Report. (Pubmed Central) -  Jul 1, 2024   
    In response, he was treated with biological agents, such as anti-IL-23 and IL-17 antibodies, risankizumab, and secukinumab, respectively, and achieved long-term survival with continued treatment with atezolizumab. This case report suggests that biological agents might be the best course of treatment against autoimmune-related adverse events caused by ICI therapy.
  • ||||||||||  Journal, Metastases:  Role of liver resection in the era of advanced systemic therapy for hepatocellular carcinoma. (Pubmed Central) -  Jul 1, 2024   
    Using more potent immuno-checkpoint inhibitors (ICIs), at least 4 phase III trials of adjuvant immunotherapy are ongoing: nivolumab, durvalumab/ bevacizumab, pembrolizumab, and atezolizumab+bevacizumab...There are 2 neoadjuvant trials for technically or oncologically unresectable HCCs ongoing in Japan: the LENS-HCC trial using lenvatinib and the RACB study using atezolizumab+bevacizumab...They obtained a Japanese consensus on this issue that has been published on the websites of JLCA and JSHPBS. The definition of resectability or borderline resectability provides a common language regarding advanced HCC for investigators and is a useful tool for future clinical trials.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Clinical, Retrospective data, Journal:  PD-L1 inhibitor versus PD-1 inhibitor plus bevacizumab with transvascular intervention in unresectable hepatocellular carcinoma. (Pubmed Central) -  Jun 28, 2024   
    Both atezolizumab (a PD-L1 inhibitor) plus bevacizumab (A+B) and sintilimab (a PD-1 inhibitor) plus bevacizumab (S+B) are recommended as the first-line regimen for advanced hepatocellular carcinoma (HCC) in China...No significant differences were observed in grade 3-4 TRAEs between groups. Either PD-L1 or PD-1 inhibitor plus bevacizumab combined with TACE-HAIC have similarly excellent therapeutic efficacy with manageable adverse events, representing promising treatment options for uHCC.
  • ||||||||||  Journal, BRCA Biomarker, PARP Biomarker, PD(L)-1 Biomarker:  Highlights from the 2024 ASCO Genitourinary Symposium: focus on urothelial and prostate cancer. (Pubmed Central) -  Jun 27, 2024   
    For UC, insights emerged from adjuvant pembrolizumab for muscle-invasive urothelial carcinoma, and from the efficacy of the EV-302 study of enfortumab vedotin +pembrolizumab in the metastatic setting...In metastatic castration-resistant PC, highlights included a novel combo (cabozantinib+atezolizumab) for poor prognosis patients; confirmed benefits of ARSI+PARPi in BRCA-mutated patients; and safety considerations for ARSI treatments. The symposium continued its role as an indispensable platform for shaping specialized oncological care.
  • ||||||||||  Imdelltra (tarlatamab-dlle) / Amgen, Imfinzi (durvalumab) / AstraZeneca, Tecentriq (atezolizumab) / Roche
    Review, Journal, IO biomarker:  The Evolving Scenario of ES-SCLC Management: From Biology to New Cancer Therapeutics. (Pubmed Central) -  Jun 27, 2024   
    Moreover, SCLC can also develop intratumoral heterogeneity linked mainly to the concept of cellular plasticity, mostly due to the development of resistance to therapies. The aim of this review is to quickly present the current standard of care of ES-SCLC, to focus on the molecular landscapes and subtypes of SCLC, subsequently present the most promising therapeutic strategies under investigation, and finally recap the future directions of ongoing clinical trials for this aggressive disease which still remains a challenge.
  • ||||||||||  Bavencio (avelumab) / EMD Serono, Tecentriq (atezolizumab) / Roche
    Journal, Heterogeneity, PD(L)-1 Biomarker, IO biomarker:  PD-L1 has a heterogeneous and dynamic expression in gastric cancer with implications for immunoPET. (Pubmed Central) -  Jun 25, 2024   
    Anti-PD-L1 immunoPET was able to visualize gastric tumors, and PD-L1 glycosylation has significant implications for antibody recognition. These insights contribute to demonstrating the complexities of PD-L1 in gastric cancer, holding relevance for refining PD-L1 imaging-based approaches.
  • ||||||||||  Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Cytovene (ganciclovir) / Roche, Tecentriq (atezolizumab) / Roche
    Journal:  Unilateral, Sectoral Retinal Metastasis of Small-Cell Lung Cancer Mimicking Viral Retinitis. (Pubmed Central) -  Jun 24, 2024   
    Retinal metastasis should be considered in patients initially diagnosed with viral retinitis who fail to improve despite antiviral therapy, particularly if they have a known history of malignancy. Furthermore, retinal metastasis of SCLC potentially could be misdiagnosed histopathologically as retinoblastoma if the patient's history is unknown and appropriate immunohistochemical stains are not performed.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS, Tecentriq (atezolizumab) / Roche
    Review, Journal, PD(L)-1 Biomarker, IO biomarker:  The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer. (Pubmed Central) -  Jun 23, 2024   
    Perioperative immunotherapy, in combination with chemotherapy, is safe and improves outcomes in patients with resectable NSCLC. Questions regarding patient selection, the need for adjuvant ICI therapy after neoadjuvant chemoimmunotherapy, and the duration of perioperative immunotherapy remain to be answered by future trials.
  • ||||||||||  Review, Journal, Metastases:  Hepatocellular Carcinoma: Beyond the Border of Advanced Stage Therapy. (Pubmed Central) -  Jun 19, 2024   
    This review highlights the efficacy of multikinase inhibitors and immune checkpoint inhibitors in monotherapy and combination therapy through the analysis of phase II, and III clinical trials, targeting the key molecular pathways involved in cellular signaling and immune response for the prospective treatment of advanced and unresectable HCC and discusses the upcoming combinations of immune checkpoint inhibitors-tyrosine kinase inhibitors and immune checkpoint inhibitors-vascular endothelial growth factor inhibitors. Finally, the hidden challenges with pharmacological therapy for HCC, feasible solutions for the future, and implications of possible presumptions to develop drugs for HCC treatment are reported.
  • ||||||||||  Journal:  Utilization of Immunotherapy as a Neoadjuvant Therapy for Liver Transplant Recipients with Hepatocellular Carcinoma. (Pubmed Central) -  Jun 19, 2024   
    All patients received ICPI including atezolizumab/bevacizumab (N = 4), nivolumab/ipilimumab (N = 1), and nivolumab as monotherapy (N = 1)...All patients received tacrolimus plus mycophenolate as immunosuppressant (IS) therapy post-OLT and one patient received prednisone as additional IS...In addition, this study illustrated the importance of timing for the administration of ICPI before OLT. Given the lack of conclusive evidence in this therapeutic area, we believe that our study lays the groundwork for prospective trials to further examine the impact of ICPI prior to OLT.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Review, Journal, Real-world evidence, Real-world effectiveness, Real-world, Metastases:  Real-World Effectiveness of First Line Lenvatinib Therapy in Advanced Hepatocellular Carcinoma: Current Insights. (Pubmed Central) -  Jun 17, 2024   
    Despite the approval of immunotherapy in 2020, specifically the combination of atezolizumab and bevacizumab following the IMbrave150 trial, tyrosine kinase inhibitors remain an indispensable class of agents in the landscape of hepatocellular carcinoma treatment. This comprehensive review delves into various facets of lenvatinib utilization in hepatocellular carcinoma, shedding light on real-world data, addressing challenges, and providing insights into strategies to overcome these obstacles.
  • ||||||||||  Tecentriq (atezolizumab) / Roche
    Journal, PD(L)-1 Biomarker, IO biomarker:  Isolated Pericardial Effusion Without Associated Myocarditis in a Small-Cell Lung Cancer Patient Undergoing Atezolizumab Therapy. (Pubmed Central) -  Jun 13, 2024   
    Following successful management, including oxygen support and a prednisone taper, chemotherapy without immunotherapy was resumed after a one-week delay. This rare case underscores the significance of promptly utilizing multimodality imaging with timely cardiology intervention, a prompt pericardial fluid analysis in diagnosing cardiac irAEs, and management leading to improved patient outcomes.
  • ||||||||||  Avastin (bevacizumab) / Roche, tiragolumab (RG6058) / Roche, Tecentriq (atezolizumab) / Roche
    Clinical, P3 data, Journal, Metastases:  IMbrave152/SKYSCRAPER-14: a Phase III study of atezolizumab, bevacizumab (Pubmed Central) -  Jun 11, 2024   
    P3
    Therapeutic targeting of TIGIT, which is highly expressed in these cells, with tiragolumab may overcome the immunosuppressive environment and improve clinical benefit, a hypothesis supported by positive efficacy signals in the Phase Ib/II MORPHEUS-Liver study. This paper describes the rationale and design of IMbrave152/SKYSCRAPER-14, a randomized, double-blind, placebo-controlled Phase III study comparing atezolizumab and bevacizumab with tiragolumab or placebo in patients with HCC and no prior systemic treatment.Clinical Trial Registration: NCT05904886 (ClinicalTrials.gov).
  • ||||||||||  Tagrisso (osimertinib) / AstraZeneca, Tecentriq (atezolizumab) / Roche
    Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker, Surgery:  Relative efficacies of EGFR-TKIs and immune checkpoint inhibitors for treatment of recurrent non-small cell lung cancer after surgery. (Pubmed Central) -  Jun 4, 2024   
    EGFR-TKIs and ICIs are effective for treating recurrent NSCLC after surgery. Although adjuvant chemotherapy for completely resected pathological stage II to IIIA NSCLC, atezolizumab or osimertinib, has also been recently approved as adjuvant chemotherapy, there is a risk that patients who relapse after adjuvant chemotherapy will have less choice.
  • ||||||||||  Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
    Review, Journal:  Neoadjuvant and adjuvant systemic therapy in HCC: Current status and the future. (Pubmed Central) -  Jun 3, 2024   
    Conversely, the use of immunotherapy is currently discouraged after liver transplantation, given the high risk of graft rejection and death. The increasing complexity of HCC management and increased consideration of (neo)adjuvant strategies highlight the critical role of multidisciplinary care when making these decisions.
  • ||||||||||  Clinical, Retrospective data, Review, Journal:  Acute kidney injury associated with anti-PD-1 and anti-PD-L1 drugs: a meta-analysis of randomized clinical trials. (Pubmed Central) -  Jun 3, 2024   
    In the analyses by class and drug type, programmed cell death 1 monoclonal antibody (anti-PD-1) showed an increased risk of 2.11 (95%CI 1.26-3.52), and pembrolizumab demonstrated a risk of AKI (RR= 2.77, 95%CI 1.46-5.26)...These findings suggest that ICI use is associated with an increased risk of AKI and that anti-PD-1 use is associated with a higher incidence of renal adverse events than programmed cell death ligand 1 monoclonal antibody (anti-PD-L1). Studies with adequate power and well-defined criteria for acute interstitial nephritis, nowadays taken as a synonym for AKI related to ICI, are necessary.
  • ||||||||||  Clinical, Journal:  The role of immunotherapy in urological cancers. (Pubmed Central) -  May 31, 2024   
    Considering ongoing randomized clinical trials, immunotherapeutic agents promise to transform the uro-oncology field significantly. In this review, we aimed to summarize the role of immunotherapy in urothelial, renal and prostate cancer in the light of randomized clinical trials.
  • ||||||||||  Tagrisso (osimertinib) / AstraZeneca
    Journal, PD(L)-1 Biomarker:  ATTLAS, IMpower151 and ORIENT-31: Dusting off IMpower150 for Post-Osimertinib in EGFR-Mutated NSCLC? (Pubmed Central) -  May 31, 2024   
    The retrospective subgroup analysis of IMpower150 indicated that the quad regimen (carboplatin, paclitaxel, bevacizumab, atezolizumab) improved PFS and overall survival (OS) in patients with EGFR-mutant NSCLC who progressed on first-generation EGFR-TKIs...MARIPOSA-2 provided the first randomized trial post-osimertinib in EGFR-mutant NSCLC patients with another quad regimen (platinum, pemetrexed, lazertinib, amivantamab)...Here, we discuss how the results of IMpower151 and ATTLAS may rejuvenate interest in a non-EGFR containing quad regimen as a potential post-osimertinib monotherapy treatment. Randomized trials comparing the results of these studies, including the quad regimen of MARIPOSA-2 versus the quad regimen of IMpower151/Impower150/ATTLAS in post-osimertinib (or other 3G EGFR-TKI) progression, are urgently needed.
  • ||||||||||  MULTICENTER STUDY ON RHEUMATOLOGICAL MANIFESTATIONS IN CANCER PATIENTS TREATED WITH IMMUNOTHERAPY () -  May 29, 2024 - Abstract #EULAR2024EULAR_4377;    
    The safety of ICIs is dependent on their types as well as on the types of cancer. The immunotherapy treatments received were PD-1 inhibitors: Pembrolizumab (48.2%) and Nivolumab (41.1%) and PDL-1 inhibitors: Atezolizumab (7.1%) and Durvalumab (3.6%)...Regarding the treatment received, 65.5% received corticosteroids as indicated by Rheumatology, with an average prednisone dose in the last 6 months of 5.86